Ming G. Chai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ming G. Chai has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Erica K. Sloan
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
3 shared publications Jason A. Roberts
Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
3 shared publicationsMenino O. Cotta
Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
3 shared publicationsCorina Kim-Fuchs
Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
2 shared publications- Steven A. Stacker
Sir Peter MacCallum Department of Oncology
2 shared publications Tara Karnezis
Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria 3010, Australia
2 shared publications
Latest Publications
- 20 January 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 48 (6) , 789-794
Extracorporeal Membrane Oxygenation Can Affect Posaconazole Exposure in Critically Ill Patients
Background: Posaconazole is an antifungal agent used to prevent or treat invasive fungal infections (IFIs) in critically ill patients, including those receiving extracorporeal membrane oxygenation (ECMO). However, in vitro data suggest that posaconazole is extensively sequestered in ECMO circuits. The aim of this study was to determine the impact of ECMO on posaconazole concentrations in critically ill patients. Methods: The authors conducted a retrospective cohort study involving patients receiving intravenous posaconazole in the intensive care unit from January 2014 to July 2024. Posaconazole concentrations at the first sampling and the proportion of patients achieving target concentrations for prophylaxis (>0.7 mg/L) and treatment (>1 mg/L) of IFI were assessed. Patients receiving ECMO were compared with non-ECMO patients. In addition, the impact of ECMO initiation or decannulation on posaconazole concentrations was examined. Results: In total, 19 patients (8 ECMO and 11 non-ECMO) were included. ECMO patients had lower posaconazole concentrations (median [interquartile range], 0.7 [0.5–0.7] mg/L versus 1.2 [0.7–1.4] mg/L, P = 0.04) and were less likely to reach therapeutic concentrations (13% versus 64%, P = 0.04). Fewer ECMO patients achieved concentrations required for prophylaxis, although this difference was not statistically significant (50% versus 82%, P = 0.17). ECMO initiation was associated with a reduction in posaconazole concentration ( n = 1), whereas decannulation was associated with an increase ( n = 3). Conclusions: ECMO patients may be at an increased risk of subtherapeutic posaconazole concentrations for treating IFI, and ECMO decannulation may increase concentrations. Close therapeutic drug monitoring is recommended, especially during ECMO initiation and decannulation, to ensure posaconazole concentrations are appropriate for treating or preventing IFI.
- 20 January 2026
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 48 (6) , 789-794
Extracorporeal Membrane Oxygenation Can Affect Posaconazole Exposure in Critically Ill Patients
Background: Posaconazole is an antifungal agent used to prevent or treat invasive fungal infections (IFIs) in critically ill patients, including those receiving extracorporeal membrane oxygenation (ECMO). However, in vitro data suggest that posaconazole is extensively sequestered in ECMO circuits. The aim of this study was to determine the impact of ECMO on posaconazole concentrations in critically ill patients. Methods: The authors conducted a retrospective cohort study involving patients receiving intravenous posaconazole in the intensive care unit from January 2014 to July 2024. Posaconazole concentrations at the first sampling and the proportion of patients achieving target concentrations for prophylaxis (>0.7 mg/L) and treatment (>1 mg/L) of IFI were assessed. Patients receiving ECMO were compared with non-ECMO patients. In addition, the impact of ECMO initiation or decannulation on posaconazole concentrations was examined. Results: In total, 19 patients (8 ECMO and 11 non-ECMO) were included. ECMO patients had lower posaconazole concentrations (median [interquartile range], 0.7 [0.5–0.7] mg/L versus 1.2 [0.7–1.4] mg/L, P = 0.04) and were less likely to reach therapeutic concentrations (13% versus 64%, P = 0.04). Fewer ECMO patients achieved concentrations required for prophylaxis, although this difference was not statistically significant (50% versus 82%, P = 0.17). ECMO initiation was associated with a reduction in posaconazole concentration ( n = 1), whereas decannulation was associated with an increase ( n = 3). Conclusions: ECMO patients may be at an increased risk of subtherapeutic posaconazole concentrations for treating IFI, and ECMO decannulation may increase concentrations. Close therapeutic drug monitoring is recommended, especially during ECMO initiation and decannulation, to ensure posaconazole concentrations are appropriate for treating or preventing IFI.
- 4 June 2024
- Published by University of Queensland Library
Personalising antimicrobial therapy in critically ill patients using Bayesian dosing software
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 4 June 2024
- Published by University of Queensland Library
Personalising antimicrobial therapy in critically ill patients using Bayesian dosing software
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 13 March 2024
- Published by Georg Thieme Verlag KG in Applied Clinical Informatics
- Vol. 15 (02) , 388-396
Factors Influencing Integration and Usability of Model-Informed Precision Dosing Software in the Intensive Care Unit
Background Antimicrobial dosing in critically ill patients is challenging and model-informed precision dosing (MIPD) software may be used to optimize dosing in these patients. However, few intensive care units (ICU) currently adopt MIPD software use. Objectives To determine the usability of MIPD software perceived by ICU clinicians and identify implementation barriers and enablers of software in the ICU. Methods Clinicians (pharmacists and medical staff) who participated in a wider multicenter study using MIPD software were invited to participate in this mixed-method study. Participants scored the industry validated Post-study System Usability Questionnaire (PSSUQ, assessing software usability) and Technology Acceptance Model 2 (TAM2, assessing factors impacting software acceptance) survey. Semistructured interviews were used to explore survey responses. The framework approach was used to identify factors influencing software usability and integration into the ICU from the survey and interview data. Results Seven of the eight eligible clinicians agreed to participate in the study. The PSSUQ usability scores ranked poorer than the reference norms (2.95 vs. 2.62). The TAM2 survey favorably ranked acceptance in all domains, except image. Qualitatively, key enablers to workflow integration included clear and accessible data entry, visual representation of recommendations, involvement of specialist clinicians, and local governance of software use. Barriers included rigid data entry systems and nonconformity of recommendations to local practices. Conclusion Participants scored the MIPD software below the threshold that implies good usability. Factors such as availability of software support by specialist clinicians was important to participants while rigid data entry was found to be a deterrent.
- 13 March 2024
- Published by Georg Thieme Verlag KG in Applied Clinical Informatics
- Vol. 15 (02) , 388-396
Factors Influencing Integration and Usability of Model-Informed Precision Dosing Software in the Intensive Care Unit
Background Antimicrobial dosing in critically ill patients is challenging and model-informed precision dosing (MIPD) software may be used to optimize dosing in these patients. However, few intensive care units (ICU) currently adopt MIPD software use. Objectives To determine the usability of MIPD software perceived by ICU clinicians and identify implementation barriers and enablers of software in the ICU. Methods Clinicians (pharmacists and medical staff) who participated in a wider multicenter study using MIPD software were invited to participate in this mixed-method study. Participants scored the industry validated Post-study System Usability Questionnaire (PSSUQ, assessing software usability) and Technology Acceptance Model 2 (TAM2, assessing factors impacting software acceptance) survey. Semistructured interviews were used to explore survey responses. The framework approach was used to identify factors influencing software usability and integration into the ICU from the survey and interview data. Results Seven of the eight eligible clinicians agreed to participate in the study. The PSSUQ usability scores ranked poorer than the reference norms (2.95 vs. 2.62). The TAM2 survey favorably ranked acceptance in all domains, except image. Qualitatively, key enablers to workflow integration included clear and accessible data entry, visual representation of recommendations, involvement of specialist clinicians, and local governance of software use. Barriers included rigid data entry systems and nonconformity of recommendations to local practices. Conclusion Participants scored the MIPD software below the threshold that implies good usability. Factors such as availability of software support by specialist clinicians was important to participants while rigid data entry was found to be a deterrent.
- Open Access
- 12 August 2023
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 42 (6) , 101296
Efficiency of dosing software using Bayesian forecasting in achieving target antibiotic exposures in critically ill patients, a prospective cohort study
- 12 August 2023
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 42 (6) , 101296
Open AccessEfficiency of dosing software using Bayesian forecasting in achieving target antibiotic exposures in critically ill patients, a prospective cohort study
- 14 April 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 28 (9) , 1211-1224
Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs
- 14 April 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 28 (9) , 1211-1224
Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs
- Open Access
- 7 July 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (7) , 638
What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?
Antimicrobial dosing in the intensive care unit (ICU) can be problematic due to various challenges including unique physiological changes observed in critically ill patients and the presence of pathogens with reduced susceptibility. These challenges result in reduced likelihood of standard antimicrobial dosing regimens achieving target exposures associated with optimal patient outcomes. Therefore, the aim of this review is to explore the various methods for optimisation of antimicrobial dosing in ICU patients. Dosing nomograms developed from pharmacokinetic/statistical models and therapeutic drug monitoring are commonly used. However, recent advances in mathematical and statistical modelling have resulted in the development of novel dosing software that utilise Bayesian forecasting and/or artificial intelligence. These programs utilise therapeutic drug monitoring results to further personalise antimicrobial therapy based on each patient’s clinical characteristics. Studies quantifying the clinical and cost benefits associated with dosing software are required before widespread use as a point-of-care system can be justified.
- 7 July 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (7) , 638
Open AccessWhat Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?
Antimicrobial dosing in the intensive care unit (ICU) can be problematic due to various challenges including unique physiological changes observed in critically ill patients and the presence of pathogens with reduced susceptibility. These challenges result in reduced likelihood of standard antimicrobial dosing regimens achieving target exposures associated with optimal patient outcomes. Therefore, the aim of this review is to explore the various methods for optimisation of antimicrobial dosing in ICU patients. Dosing nomograms developed from pharmacokinetic/statistical models and therapeutic drug monitoring are commonly used. However, recent advances in mathematical and statistical modelling have resulted in the development of novel dosing software that utilise Bayesian forecasting and/or artificial intelligence. These programs utilise therapeutic drug monitoring results to further personalise antimicrobial therapy based on each patient’s clinical characteristics. Studies quantifying the clinical and cost benefits associated with dosing software are required before widespread use as a point-of-care system can be justified.
- Open Access
- 1 March 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 10634
Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination
Chronic stress induces signalling from the sympathetic nervous system (SNS) and drives cancer progression, although the pathways of tumour cell dissemination are unclear. Here we show that chronic stress restructures lymphatic networks within and around tumours to provide pathways for tumour cell escape. We show that VEGFC derived from tumour cells is required for stress to induce lymphatic remodelling and that this depends on COX2 inflammatory signalling from macrophages. Pharmacological inhibition of SNS signalling blocks the effect of chronic stress on lymphatic remodellingin vivoand reduces lymphatic metastasis in preclinical cancer models and in patients with breast cancer. These findings reveal unanticipated communication between stress-induced neural signalling and inflammation, which regulates tumour lymphatic architecture and lymphogenous tumour cell dissemination. These findings suggest that limiting the effects of SNS signalling to prevent tumour cell dissemination through lymphatic routes may provide a strategy to improve cancer outcomes.
- 1 March 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 10634
Open AccessChronic stress in mice remodels lymph vasculature to promote tumour cell dissemination
Chronic stress induces signalling from the sympathetic nervous system (SNS) and drives cancer progression, although the pathways of tumour cell dissemination are unclear. Here we show that chronic stress restructures lymphatic networks within and around tumours to provide pathways for tumour cell escape. We show that VEGFC derived from tumour cells is required for stress to induce lymphatic remodelling and that this depends on COX2 inflammatory signalling from macrophages. Pharmacological inhibition of SNS signalling blocks the effect of chronic stress on lymphatic remodellingin vivoand reduces lymphatic metastasis in preclinical cancer models and in patients with breast cancer. These findings reveal unanticipated communication between stress-induced neural signalling and inflammation, which regulates tumour lymphatic architecture and lymphogenous tumour cell dissemination. These findings suggest that limiting the effects of SNS signalling to prevent tumour cell dissemination through lymphatic routes may provide a strategy to improve cancer outcomes.
- 28 June 2013
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 76,p. e50395
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
Pancreatic cancer has an extremely poor five-year survival rate of 4-6%. New therapeutic options are critically needed and depend on improved understanding of pancreatic cancer biology. To better understand the interaction of cancer cells with the pancreatic microenvironment, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression. Luciferase-tagged pancreatic cancer cells are resuspended in Matrigel and delivered into the pancreatic tail during laparotomy. Matrigel solidifies at body temperature to prevent leakage of cancer cells during injection. Primary tumor growth and metastasis to distant organs are monitored following injection of the luciferase substrate luciferin, using in vivo imaging of bioluminescence emission from the cancer cells. In vivo imaging also may be used to track primary tumor recurrence after resection. This orthotopic model is suited to both syngeneic and xenograft models and may be used in pre-clinical trials to investigate the impact of novel anti-cancer therapeutics on the growth of the primary pancreatic tumor and metastasis.
- 28 June 2013
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 76,p. e50395
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
Pancreatic cancer has an extremely poor five-year survival rate of 4-6%. New therapeutic options are critically needed and depend on improved understanding of pancreatic cancer biology. To better understand the interaction of cancer cells with the pancreatic microenvironment, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression. Luciferase-tagged pancreatic cancer cells are resuspended in Matrigel and delivered into the pancreatic tail during laparotomy. Matrigel solidifies at body temperature to prevent leakage of cancer cells during injection. Primary tumor growth and metastasis to distant organs are monitored following injection of the luciferase substrate luciferin, using in vivo imaging of bioluminescence emission from the cancer cells. In vivo imaging also may be used to track primary tumor recurrence after resection. This orthotopic model is suited to both syngeneic and xenograft models and may be used in pre-clinical trials to investigate the impact of novel anti-cancer therapeutics on the growth of the primary pancreatic tumor and metastasis.
- 1 February 2012
- Published by Elsevier in Cancer Cell
- Vol. 21 (2) , 181-195
VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium
- 1 February 2012
- Published by Elsevier in Cancer Cell
- Vol. 21 (2) , 181-195
VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium